Incyte Corporation (LON:0J9P)
83.62
+0.41 (0.49%)
At close: Sep 16, 2025
Incyte Revenue
Incyte had revenue of $1.22B USD in the quarter ending June 30, 2025, with 16.46% growth. This brings the company's revenue in the last twelve months to $4.58B, up 18.87% year-over-year. In the year 2024, Incyte had annual revenue of $4.24B with 14.76% growth.
Revenue (ttm)
$4.58B
Revenue Growth
+18.87%
P/S Ratio
3.62
Revenue / Employee
$1.75M
Employees
2,617
Market Cap
12.12B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Incyte News
- 7 days ago - Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress - Business Wire
- 8 days ago - Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade. - Barrons
- 8 days ago - Incyte Corporation (INCY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 13 days ago - Incyte Corporation (INCY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 13 days ago - Incyte (INCY) Rating Affirmed with Increased Price Target by B of A Securities | INCY Stock News - GuruFocus
- 14 days ago - Incyte Corporation (INCY) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 14 days ago - Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa - Business Wire
- 15 days ago - Why Incyte Corp (INCY) Is Set to Outperform the Market: Insights into Financial Growth and ... - GuruFocus